drugset / Trial / NCT06906029

Abdominal aBscess Catheter Sclerotherapy (ABCS)

NCT06906029 ↗

Phase 1/2 Active not recruiting 60 enrolled University of Alabama at Birmingham Argon Medical Devices · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a single center, two arm phase I/II clinical trial exploring the use of chemical sclerosants (ethanol and povidone iodine) in decreasing the time needed for catheter drainage for patients with non-fistulous intraabdominal abscesses. The target study sample size is 60 patients, 30 in each arm and abscess size is to be a minimum of 3cm in all 3 dimensions. The primary outcomes of interest will be tolerability and need for catheter reinsertion by one week post intervention.

Timeline

Start
2025-12-21
Primary completion
2028-07
Completion
2028-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ethanol Other / unclassified — Other
Comparator Povidone-Iodine Other / unclassified — Other

Indications